Specialized Genetic Testing CombiMatrix’s focus on cytogenomic and genetic diagnostic testing, including preimplantation genetic screening and miscarriage analysis, presents opportunities to expand partnerships with fertility clinics, obstetric centers, and pediatric specialists seeking advanced diagnostic solutions.

Recent Technological Launches The company’s launch of SNP microarray testing for intrauterine fetal demise and PGD demonstrates innovation in prenatal diagnostics, which can be leveraged to attract healthcare providers looking for cutting-edge genetic testing services.

Acquisition and Growth Having been acquired by Invitae, CombiMatrix benefits from a broader industry network and increased credibility, opening doors to new clients in the genetic testing space and potential collaborative opportunities with related biotech firms.

Target Market Focus With a specialized service portfolio in prenatal and pediatric genetic testing, there is a significant sales opportunity to tailor outreach to fertility clinics, pediatricians, and obstetricians aiming to improve patient outcomes with precise diagnostics.

Financial and Industry Position Operating with revenues between 10 and 25 million dollars and positioned among industry giants, CombiMatrix offers a compelling value proposition for strategic partnerships, OEM arrangements, or service expansion within the competitive biotech testing landscape.